Article
Safety of FLT3 inhibitors in patients with acute myeloid leukemia.
Expert review of hematology - 1 Sept 2021
Cerchione Claudio, Peleteiro Raíndo Andrés, Mosquera Orgueira Adrián, Mosquera Torre Alicia, Bao Pérez Laura, Marconi Giovanni, Isidori Alessandro, Pérez Encinas Manuel Mateo, Martinelli Giovanni
Abstract excerpt
Introduction: Acute myeloblastic leukemia (AML) is the most frequent type of acute leukemia in adults with an incidence of 4.2 cases per 100,000 inhabitants and poor 5-year survival. Patients with mutations in the FMS-like tyrosine kinase 3 (FLT3) gene have poor survival and higher relapse rates...
Topics
- Antineoplastic Agents
- Humans
- Leukemia, Myeloid, Acute
- Mutation
- Protein Kinase Inhibitors
- Sorafenib
- fms-Like Tyrosine Kinase 3